Gadi Levin - 01 Aug 2022 Form 3 Insider Report for BriaCell Therapeutics Corp. (BCTX)

Reporting relationship
CFO & Secretary
Issuer ticker
BCTX
Reported as of
01 Aug 2022
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
01 Aug 2022, 16:10:12 UTC
Prior SEC filing
13 Jan 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Gadi Levin

Key filing fact

Gadi Levin filed Form 3 for BriaCell Therapeutics Corp. (BCTX) on 01 Aug 2022.

Key facts

  • This page summarizes Gadi Levin's Form 3 filing for BriaCell Therapeutics Corp. (BCTX).
  • 0 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 01 Aug 2022, 16:10.

Change

  • Previous filing in this sequence was filed on 13 Jan 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCTX holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,810
Date
01 Aug 2022
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCTX holding Derivative

Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Aug 2022
Ownership
Direct
Underlying class
Common Shares
Underlying amount
75,000
Exercise price
$4.24
BCTX holding Derivative

Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Aug 2022
Ownership
Direct
Underlying class
Common Shares
Underlying amount
20,000
Exercise price
$4.71
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Option vests quarterly for 2 years from the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .